Tango Therapeutics (TNGX) R&D chief exercises options, sells 12,000 shares

NodeGuardian · 2026-03-28T03:59:38+00:00

Crystal Adam, President of Tango Therapeutics, exercised stock options for 12,000 shares at $5.20 each and sold them for $20.11 per share under a Rule 10b5-1 plan, retaining a significant number of shares and options post-sale.

NodeGuardian

2026-03-28 03:59:38

Abstract generation in progress

Crystal Adam, President of R&D at Tango Therapeutics (TNGX), exercised stock options to acquire 12,000 shares at $5.20 each and subsequently sold all 12,000 shares in open-market transactions for a weighted-average price of $20.11 per share on March 25, 2026. These transactions were performed under a pre-arranged Rule 10b5-1 trading plan. Post-sale, Adam retains 112,622 shares of common stock and 460,500 stock options, indicating the sale was a relatively minor part of her overall holdings.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.